Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017; New Report Launched

DrugPipeline.net has announced the addition of “Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017” research report to their website www.DrugPipeline.net


Bangalore, India -- (SBWIRE) -- 06/12/2017 -- Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 44, 51, 1, 3, 53, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 10 and 7 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).

- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 791 pages "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017" report covers Introduction, Chronic Lymphocytic Leukemia (CLL) - Overview, Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development, Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment, Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development, Chronic Lymphocytic Leukemia (CLL) - Drug Profiles, Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones, Appendix. This report Covered Companies few are - 4SC AG, AbbVie Inc, ABL Bio Inc, ACEA Biosciences Inc, ADC Therapeutics Sarl, Aeglea BioTherapeutics Inc, Altor BioScience Corp.

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/chronic-lymphocytic-leukemia-cll-pipeline-review-h1-2017

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.